medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-13-34-37medsovet-1982Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONПРОТИВОТРОМБОТИЧЕСКАЯ ПРОФИЛАКТИКА У ЖЕНЩИНЫ С ОТЯГОЩЕННЫМ АКУШЕРСКИМ И ТРОМБОТИЧЕСКИМ АНАМНЕЗОМ. КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕANTITHROMBOTIC PREVENTION IN WOMEN WITH MEDICAL HISTORY SIGNIFICANT FOR OBSTETRIC AND THROMBOTIC EVENTS. CLINICAL OBSERVATIONХизроеваД. Х.KhizroevaD. K.

д.м.н., профессор,

 

PhD in medicine, Prof.,

Moscow

Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава РоссииРоссияSechenov First Moscow State Medical University of the Ministry of Health of RussiaRussian Federation2017071020170133437Copyright © Хизроева Д.Х., 20172017Хизроева Д.Х.Khizroeva D.K.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1982

В статье представлен клинический пример ведения беременности у женщины с отягощенным акушерским и тромботическим анамнезом. После тщательно проведенного обследования системы гемостаза была выявлена роль генетической и приобретенной тромбофилии. С современной точки зрения тромбофилия считается этиопатогенетическим фактором для  широкого спектра заболеваний и синдромов – синдрома потери плода, преэклампсии, тромбоэмболических осложнений гормональной контрацепции и гормональной заместительной терапии. Обсуждается роль антикоагулянтной и антиагрегантной терапии, в частности применение дипиридамола в акушерской практике.

The article presents a clinical case of management of pregnancy in a woman with medical history signficant for obstetric and thrombotic events. After a thorough examination of the hemostatic system the role of genetic and acquired thrombophilia was identified. From a modern point of view thrombophilia is considered to be the etiopathogenetic factor for a wide range of diseases and syndromes – fetal loss syndrome, preeclampsia, thromboembolic complications of hormonal contraception and hormonal replacement therapy. The role of anticoagulant and antiplatelet therapy is discussed, in particular the use of dipyridamole in  obstetric practice.

дипиридамолбемипарин натриятромбофилияантифосфолипидный синдромгипергомоцистеинемияишемический инсультантенатальная гибель плодаdipyridamolebemiparin sodiumthrombophiliaantiphospholipid syndromehyperhomocysteinemiaischemic strokeantenatal fetal deathReferencesCiacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem, 2015, 15(9): 822-9.Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem, 2015, 15(9): 822-9.Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews, 2007.Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews, 2007.Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol, 1996 Dec, 119(7): 1438-46.Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol, 1996 Dec, 119(7): 1438-46.Kam A, Razmovski-Naumovski V, Zhou X, Troung J, Chan K.Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci, 2015, 18(5): 871-81.Kam A, Razmovski-Naumovski V, Zhou X, Troung J, Chan K.Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci, 2015, 18(5): 871-81.Massaro M, Scoditti E, Carluccio MA, Pellegrino M, Calabriso N, Storelli C, Martines G, De Caterina R. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost, 2013 Feb, 109(2): 280-9. doi: 10.1160/TH12-05-0326.Massaro M, Scoditti E, Carluccio MA, Pellegrino M, Calabriso N, Storelli C, Martines G, De Caterina R. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost, 2013 Feb, 109(2): 280-9. doi: 10.1160/TH12-05-0326.Taddei S, Arzilli F, Arrighi P, Salvetti A. Dipyridamole decreases circulating renin-angiotensin system activity in hypertensive patients. Am J Hypertens, 1992 Jan, 5(1): 29-31.Taddei S, Arzilli F, Arrighi P, Salvetti A. Dipyridamole decreases circulating renin-angiotensin system activity in hypertensive patients. Am J Hypertens, 1992 Jan, 5(1): 29-31.Yarrington CD, Valente AM, Economy KE. Cardiovascular Management in Pregnancy: Antithrombotic Agents and Antiplatelet Agents. Circulation, 2015 Oct 6, 132(14): 1354-64.Yarrington CD, Valente AM, Economy KE. Cardiovascular Management in Pregnancy: Antithrombotic Agents and Antiplatelet Agents. Circulation, 2015 Oct 6, 132(14): 1354-64.

The authors declare that there are no conflicts of interest present.